Thomas Fowler, MD
Allergy & Immunology · Prosper, TXNPI 1861948176
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,898 of the $6,720 with a category attached, or 87.8%. It is spread thinly across 35 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for allergy & immunology clinicians in TX, where the typical reported total is $5,878.
Across 267 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$886
- Sanofi$770
- Takeda Pharmaceuticals U.S.A., Inc.$730
- GSK$696
- AstraZeneca$588
- Biocryst US Sales Co., LLC$507
- plus $3K from 29 others
What the payments were for
- Grants$70010%
- Food & beverage$5,89888%
- Education$1222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 46 | $886 |
| Sanofi | 4 | $770 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $730 |
| GSK | 30 | $696 |
| AstraZeneca | 27 | $588 |
| Biocryst US Sales Co., LLC | 14 | $507 |
| CSL Behring | 13 | $287 |
| Grifols USA, LLC | 13 | $266 |
| Octapharma USA, Inc. | 9 | $262 |
| Pfizer | 8 | $256 |
| Amgen(2 entities) | 13 | $248 |
| Genentech USA, Inc. | 9 | $175 |
| Pharming Healthcare, Inc. | 6 | $136 |
| Kaleo, Inc. | 5 | $120 |
| Alk-abello, Inc | 4 | $93 |
| Jubilant Hollisterstier LLC | 1 | $87 |
| Novartis | 4 | $74 |
| Biocryst Pharmaceuticals, Inc. | 3 | $68 |
| Henry Schein, Inc. | 2 | $67 |
| QOL Medical, LLC | 2 | $49 |
| Galderma Laboratories, L.p. | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Ionis Pharmaceuticals, Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| ADMA Biomanufacturing LLC | 1 | $26 |
| Covis Pharma GmbH | 1 | $25 |
| AbbVie | 1 | $22 |
| Merck | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| LEO Pharma Inc. | 1 | $18 |
| Greer Laboratories, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| Optinose US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,720 in reported general payments places this provider in the 50th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 12 | $33,239 |
| Azelastine Hcl | 14 | $758 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Prosper
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
- Serge de GolovineBellaire$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.